drugset / Trial / NCT06849947
Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
▪ Fulvestrant With Ribociclib versus Physician's choice treatments for the patients who recurred after completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer as first line treatment
Timeline
- Start
- 2026-02-01
- Primary completion
- 2031-06-30
- Completion
- 2031-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Everolimus | Small molecule | 10 mg | Oral |
| Comparator | Exemestane | Small molecule | 25 mg | Oral |
| Comparator | Fulvestrant | Small molecule | 500 mg | Intramuscular |
| Subject | Ribociclib | Small molecule | 600 mg | Oral |
| Comparator | Leuprolide | Other / unclassified | 3.75 mg | Subcutaneous |